After marijuana flops in cancer pain, investors look to the future

2/7/15–Sativex’s future as a cancer-pain treatment was somewhat dashed when GW Pharmaceuticals reported that data from the first of three phase 3 studies failed to outperform placebo. Investors will get more insight into GW Pharmaceuticals’ opportunity in the cancer-pain indication when the second trial results become available in the second quarter; however, investors might be right to temper their expectations given that the second trial is identical in design to the failed first trial. Read